BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tanaka H, Kamata N, Yamada A, Endo K, Fujii T, Yoshino T, Sugaya T, Yokoyama Y, Bamba S, Umeno J, Yanai Y, Ishii M, Kawaguchi T, Shinzaki S, Toya Y, Kobayashi T, Nojima M, Hibi T; ADJUST study group. Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease. J Gastroenterol Hepatol 2018;33:1031-8. [PMID: 29087616 DOI: 10.1111/jgh.14034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Ungar B, Ben-Shatach Z, Selinger L, Malik A, Albshesh A, Ben-Horin S, Eliakim R, Kopylov U, Carter D. Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease. United European Gastroenterol J 2020;8:167-74. [PMID: 32213067 DOI: 10.1177/2050640619878974] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
2 Sartini A, Scaioli E, Liverani E, Bellanova M, Ricciardiello L, Bazzoli F, Belluzzi A. Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy. Dig Dis Sci 2019;64:863-74. [DOI: 10.1007/s10620-018-5329-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
3 Ribaldone DG, Tribocco E, Rosso C, Armandi A, Vernero M, Bugianesi E, Astegiano M, Saracco GM, Caviglia GP. Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. J Clin Med 2021;10:3387. [PMID: 34362184 DOI: 10.3390/jcm10153387] [Reference Citation Analysis]
4 Lie MRKL, Paulides E, van der Woude CJ. Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. Int J Colorectal Dis 2020;35:1489-500. [PMID: 32592091 DOI: 10.1007/s00384-020-03663-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Ribaldone DG, Caviglia GP, Pellicano R, Vernero M, Italia A, Morino M, Saracco GM, Astegiano M. Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn’s disease: application of Lémann Index. Scandinavian Journal of Gastroenterology 2019;54:1339-45. [DOI: 10.1080/00365521.2019.1686057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Krusiński A, Grzywa-Celińska A, Szewczyk K, Grzycka-Kowalczyk L, Emeryk-Maksymiuk J, Milanowski J. Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents. Int J Inflam 2021;2021:6284987. [PMID: 33489084 DOI: 10.1155/2021/6284987] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kamperidis N, Middleton P, Tyrrell T, Stasinos I, Arebi N. Impact of therapeutic drug level monitoring on outcomes of patients with Crohn's disease treated with Infliximab: real world data from a retrospective single centre cohort study. Frontline Gastroenterol 2019;10:330-6. [PMID: 31682652 DOI: 10.1136/flgastro-2018-101024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Hisamatsu T, Suzuki Y, Kobayashi M, Hagiwara T, Kawaberi T, Ogata H, Matsui T, Watanabe M, Hibi T. Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study. Intest Res 2021;19:408-18. [PMID: 33207857 DOI: 10.5217/ir.2020.00025] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis 2018;9:147-58. [PMID: 30065812 DOI: 10.1177/2040622318772705] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
10 Endo K, Kakuta Y, Moroi R, Yamamoto K, Shiga H, Kuroha M, Naito T, Kinouchi Y, Masamune A. TL1A (TNFSF15) genotype affects the long-term therapeutic outcomes of anti-TNFα antibodies for Crohn's disease patients. JGH Open 2020;4:1108-13. [PMID: 33319044 DOI: 10.1002/jgh3.12398] [Reference Citation Analysis]
11 Kitayama M, Akazawa Y, Yoshikawa D, Higashi S, Morisaki T, Oda H, Ikeda M, Nakashima Y, Tabuchi M, Hashiguchi K, Matsushima K, Yamaguchi N, Kondo H, Nakao K, Takeshima F. Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients. Sci Rep 2020;10:12546. [PMID: 32719413 DOI: 10.1038/s41598-020-68828-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Reference Citation Analysis]
13 Laganà B, Zullo A, Scribano ML, Chimenti MS, Migliore A, Picchianti Diamanti A, Lorenzetti R, Scolieri P, Ridola L, Ortona E, Pierdominici M, Bruzzese V. Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. Front Pharmacol 2019;10:47. [PMID: 30745872 DOI: 10.3389/fphar.2019.00047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
14 Bucalo A, Rega F, Zangrilli A, Silvestri V, Valentini V, Scafetta G, Marraffa F, Grassi S, Rogante E, Piccolo A, Cucchiara S, Viola F, Bianchi L, Ottini L, Richetta A. Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers. Int J Mol Sci 2020;21:E7873. [PMID: 33114187 DOI: 10.3390/ijms21217873] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Perera S, Yang S, Stott-Miller M, Brady J. Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease. J Health Econ Outcomes Res 2018;6:96-112. [PMID: 32685575 DOI: 10.36469/9791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]